The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The company adds royalty aggregation to its R&D business.
But Enhertu is coming.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The restructured biotech’s new lead project enters phase 1.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
